185 related articles for article (PubMed ID: 37594082)
21. SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
Xue Z; Wang J; Wang Z; Liu J; Zhao J; Liu X; Zhang Y; Liu G; Zhao Z; Li W; Zhang Q; Li X; Huang B; Wang X
BMC Cancer; 2023 Jun; 23(1):589. PubMed ID: 37365560
[TBL] [Abstract][Full Text] [Related]
22. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway.
Cheng Y; Xie P
J Biochem Mol Toxicol; 2019 Nov; 33(11):e22392. PubMed ID: 31503386
[TBL] [Abstract][Full Text] [Related]
23. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
[TBL] [Abstract][Full Text] [Related]
24. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
25. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells.
Yang MH; Jung SH; Um JY; Kumar AP; Sethi G; Ahn KS
Life Sci; 2022 Apr; 295():120395. PubMed ID: 35181309
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
27. Up-regulated circular RNA hsa_circ_0067934 contributes to glioblastoma progression through activating PI3K-AKT pathway.
Xin J; Zhang XY; Sun DK; Tian LQ; Xu P
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3447-3454. PubMed ID: 31081099
[TBL] [Abstract][Full Text] [Related]
28. RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma.
Li Q; Liu X; Mao J; Liu S; Hou B; Li K; Fang D
Biochem Biophys Res Commun; 2023 Oct; 676():149-157. PubMed ID: 37517217
[TBL] [Abstract][Full Text] [Related]
29. MiR-485-5p Suppress the Malignant Characteristics of the Lung Adenocarcinoma via Targeting NADPH Quinone Oxidoreductase-1 to Inhibit the PI3K/Akt.
Chen Y; Wu L; Bao M
Mol Biotechnol; 2023 May; 65(5):794-806. PubMed ID: 36219369
[TBL] [Abstract][Full Text] [Related]
30. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
32. CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway.
Chen X; Zhu M; Zou X; Mao Y; Niu J; Jiang J; Dong T; Shi Y; Yang X; Liu P
Life Sci; 2022 Dec; 311(Pt B):121174. PubMed ID: 36396110
[TBL] [Abstract][Full Text] [Related]
33. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
[TBL] [Abstract][Full Text] [Related]
34. LncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway.
Gao XF; He HQ; Zhu XB; Xie SL; Cao Y
Neoplasma; 2019 Jul; 66(4):532-542. PubMed ID: 30943748
[TBL] [Abstract][Full Text] [Related]
35. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
[TBL] [Abstract][Full Text] [Related]
36. Modulated Gene Expression of
Zhou W; Quan JH; Gao FF; Ismail HAHA; Lee YH; Cha GH
Korean J Parasitol; 2018 Apr; 56(2):135-145. PubMed ID: 29742868
[TBL] [Abstract][Full Text] [Related]
37. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
40. A prognostic biomarker NRG1 promotes U-87 MG glioblastoma cell malignancy by inhibiting autophagy via ERBB2/AKT/mTOR pathway.
Lin JZ; Lin N; Zhao WJ
J Cell Biochem; 2023 Sep; 124(9):1273-1288. PubMed ID: 37450666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
